PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRuxolitinib
Jakafi, Jakavi(ruxolitinib)
Jakafi, Jakavi, Opzelura (ruxolitinib) is a small molecule pharmaceutical. Ruxolitinib was first approved as Jakafi on 2011-11-16. It is used to treat polycythemia vera and primary myelofibrosis in the USA. It has been approved in Europe to treat graft vs host disease, myeloproliferative disorders, polycythemia vera, and vitiligo. The pharmaceutical is active against tyrosine-protein kinase JAK1 and tyrosine-protein kinase JAK2. In addition, it is known to target tyrosine-protein kinase JAK3 and non-receptor tyrosine-protein kinase TYK2.
Download report
Favorite
COVID-19
Novartis Pharmaceuticals
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Jakafi, Opzelura
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ruxolitinib phosphate
Tradename
Company
Number
Date
Products
JAKAFIIncyteN-202192 RX2011-11-16
5 products, RLD, RS
OPZELURAIncyteN-215309 RX2021-09-21
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
jakafiNew Drug Application2023-01-31
opzeluraNew Drug Application2024-08-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
polycythemia vera—D011087D45
primary myelofibrosis—D055728D47.4
Agency Specific
FDA
EMA
Expiration
Code
RUXOLITINIB PHOSPHATE, JAKAFI, INCYTE CORP
2029-03-22PED
2028-09-22ODE-373
2026-11-24PED
2026-06-19PED
2026-05-24ODE-238
2025-12-19M-285
2025-03-22PED
2024-09-22I-872
RUXOLITINIB PHOSPHATE, OPZELURA, INCYTE CORP
2026-01-18PED
2025-07-18I-896
2025-03-21PED
2024-09-21NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Ruxolitinib Phosphate, Opzelura, Incyte Corp
116025362041-05-05U-3550
115109232040-09-04U-3505
115901372040-09-04U-3505
115901382040-06-10U-3551
107585432031-05-20DP
108698702031-05-20U-3229, U-3404
112196242031-05-20DPU-3229
115714252031-05-20DP
115901362031-05-20U-3229, U-3404
106105302028-06-12U-3229, U-3404
99747902026-12-12U-3229, U-3404
106393102026-12-12U-3229
Ruxolitinib Phosphate, Jakafi, Incyte Corp
87226932028-06-12DS, DP
88224812028-06-12U-1573, U-3226, U-3227, U-3228, U-3229, U-3230, U-3404
88290132028-06-12U-1201, U-1622, U-3227, U-3228
100164292028-06-12U-3226, U-3230
75982572027-12-24DS, DPU-3227, U-3228
84153622027-12-24DS, DP
90799122026-12-12U-3226, U-3227, U-3228, U-3229, U-3230, U-3404
98147222026-12-12U-3226, U-3230
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EJ: Janus-associated kinase (jak) inhibitors
— L01EJ01: Ruxolitinib
HCPCS
No data
Clinical
Clinical Trials
407 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EczemaD004485HP_0000964L30.93471217
DermatitisD003872HP_0011123L30.94551216
Atopic dermatitisD003876EFO_0000274L203351214
DyssomniasD020920—————1—1
ParasomniasD020447—G47.5———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Primary myelofibrosisD055728—D47.48183—126
PolycythemiaD011086EFO_0005804D75.1694—117
Polycythemia veraD011087—D45595——16
Myeloproliferative disordersD009196—D47.15111——14
LeukemiaD007938—C95781——13
ThrombocytosisD013922HP_0001894D75.834102——13
Essential thrombocythemiaD013920—D47.3492——12
Graft vs host diseaseD006086—D89.81252—211
VitiligoD014820EFO_0004208L80—44——8
Precursor cell lymphoblastic leukemia-lymphomaD054198——231——5
Show 7 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8078———11
Bronchiolitis obliterans syndromeD000092122——15———6
Myeloid leukemiaD007951—C9233———5
Breast neoplasmsD001943EFO_0003869C5025———5
Myelodysplastic syndromesD009190—D4632———5
Multiple myelomaD009101—C90.032———4
Plasma cell neoplasmsD054219——32———4
Myeloid leukemia acuteD015470—C92.023———4
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—12———3
Myeloid leukemia chronic-phaseD015466——12———3
Show 54 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———2————2
Philadelphia chromosomeD010677——1————1
Myelodysplastic-myeloproliferative diseasesD054437——1————1
Wasting syndromeD019282——1————1
CachexiaD002100HP_0004326R641————1
Pancreatic ductal carcinomaD021441——1————1
Disease progressionD018450——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pregnancy rateD018873——————22
EmergenciesD004630——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRuxolitinib
INNruxolitinib
Description
Ruxolitinib is a pyrazole substituted at position 1 by a 2-cyano-1-cyclopentylethyl group and at position 3 by a pyrrolo[2,3-d]pyrimidin-4-yl group. Used as the phosphate salt for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. It has a role as an antineoplastic agent and an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor. It is a nitrile, a pyrrolopyrimidine and a member of pyrazoles.
Classification
Small molecule
Drug classdeuterated compounds; tyrosine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Identifiers
PDB—
CAS-ID941678-49-5
RxCUI—
ChEMBL IDCHEMBL1789941
ChEBI ID66919
PubChem CID25126798
DrugBankDB08877
UNII ID82S8X8XX8H (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
JAK3
JAK3
Organism
Homo sapiens
Gene name
JAK3
Gene synonyms
NCBI Gene ID
3718
Protein name
tyrosine-protein kinase JAK3
Protein synonyms
JAK-3, Janus kinase 3, Janus kinase 3 (a protein tyrosine kinase, leukocyte), L-JAK, Leukocyte janus kinase
Uniprot ID
Q9Y6S2
Mouse ortholog
Jak3 (16453)
tyrosine-protein kinase JAK3 (Q62137)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Jakafi – Incyte
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Jakavi – Incyte
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Jakavi – Novartis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Opzelura – Incyte
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 13,262 documents
View more details
Safety
Black-box Warning
Black-box warning for: Opzelura
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
65,828 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use